atropine has been researched along with vanoxerine in 4 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (vanoxerine) | Trials (vanoxerine) | Recent Studies (post-2010) (vanoxerine) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 556 | 5 | 93 |
| Protein | Taxonomy | atropine (IC50) | vanoxerine (IC50) |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.5098 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 0.0103 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.5513 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.0969 | |
| Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | 0.073 | |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | 0.073 | |
| Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | 0.073 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0424 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.022 | |
| Transporter | Rattus norvegicus (Norway rat) | 0.114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booth, RG; Brown, RL; Bucholtz, EC; Tropsha, A; Wyrick, SD | 1 |
| Hayashi, S; Kato, A; Mizuno, K; Morita, A; Nakata, E; Ohashi, K; Yamamura, K | 1 |
| Amsler, CD; Baker, BJ; Hahn, KN; Kyle, DE; Lebar, MD; Maignan, P; McClintock, JB; Mutka, T; van Olphen, A | 1 |
| Butler, T; Dobbie, JW; Duffield, R; Hjelle, JT; Ho, AK; Miller-Hjelle, MA; Reith, M; Steidley, KR | 1 |
4 other study(ies) available for atropine and vanoxerine
| Article | Year |
|---|---|
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
Topics: Animals; Binding Sites; Binding, Competitive; Brain; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ligands; Models, Molecular; Pyrilamine; Radioligand Assay; Structure-Activity Relationship; Tetrahydronaphthalenes | 1999 |
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
Topics: Analgesics; Animals; Benzimidazoles; Drug Design; Drug Evaluation, Preclinical; Humans; Microsomes, Liver; Neuralgia; Nociceptin Receptor; Pyrroles; Rats; Receptors, Opioid; Structure-Activity Relationship | 2010 |
CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.
Topics: Antimalarials; Cell Line, Tumor; Central Nervous System Agents; Humans; Indole Alkaloids; Indoles; Plasmodium falciparum; Pyrimidines; Receptors, Serotonin | 2011 |
Multiple drug classes and hyperosmolarity alter binding of muscarinic drugs to mesothelial cells in vitro.
Topics: Animals; Atropine; Cells, Cultured; Cocaine; Cycloheximide; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Epithelium; Mannitol; Muscarinic Antagonists; N-Methylscopolamine; Osmolar Concentration; Parasympatholytics; Peritoneum; Piperazines; Quinuclidinyl Benzilate; Rabbits; Receptors, Muscarinic; Scopolamine Derivatives; Sodium Chloride | 1995 |